Riessland’ group identified NCALD as a potential SMA modifier by Genome-Wide Linkage and Transcriptome-Wide differential expression analysis performed on samples of SMA type 1 patients and fully asymptomatic people, both carrying homozygous SMN1 deletions (Riessland et al., 2017). The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.